T he 2 schizophrenia reviews in this issue are massive surveys of 2 great fields of knowledge. To read them is to feel one has absorbed all that is most relevant to the understanding of schizophrenia in 1997. The 2 fields are very different, one dealing with clinical populations and numerical comparisons, the other with chemical formulae and receptor occupancies. Is there anything they have in common? Gathered in a room, could epidemiologists and psychopharmacologists talk to one another and enjoy the conversation? Professors Häfner and an der Heiden (1) from Mannheim, Germany, explain the complexities of epidemiological studies and the importance of doing them right. They summarize the findings from across the world and then pose several answerable questions. Is social disadvantage a risk factor for schizophrenia or is it the other way around? This is an old chestnut which is perennially readdressed, but the question is given new meaning in light of the long prodrome leading up to overt schizophrenia. Professors Häfner and an der Heiden have categorized and measured this prodrome, and they conclude that schizophrenia comes first. Social consequences come later. Another question that they address is the issue of late-onset or old-age schizophrenia. Whether schizophrenia symptoms that arise in the elderly should be counted as schizophrenia and whether or not they result from factors similar in kind to those which produce adolescent-onset schizophrenia is the question. This review, like all others up to now, is unable to answer this important question. Another question is the difference between schizophrenia in men and women. Onset ages differ, but is the illness the same? These authors use their considerable expertise in this area to argue that the illness is the same, the illness features are the same, but nonillness personality features and behaviours differ. This, they argue, introduces an important connection between personality and disease. They ask yet other questions. Have rates and patterns of schizophrenia changed over the years? Is early-onset illness more severe than late-onset illness? The answers are complicated and deserve a thorough reading of their paper, their 150 references, and their informative figures and tables.
Drs Lehmann and Ban (2), professors emeritus from
McGill and Vanderbilt Universities, review the historical developments of the psychopharmacological treatment of schizophrenia and, like the epidemiologists, tell us what constitutes good research in their field. They tell us of the early period of trials and errors based on intuitive feelings of what might be causing the disease. By the mid-1930s, there were effective treatments that worked, and this can be called the dawn of modern scientific psychopharmacology-not so much finding therapies that work (although this remains the aim of clinical psychopharmacology), but finding out why partially effective treatments are, in fact, effective at all and what that teaches us about causative factors in schizophrenia. Most drugs in use today are based on serendipitous findings. What is scientifically intriguing is why they work at all, what part of the brain they do their job at, and what, exactly, is the nature of that job. Like the epidemiologists, Lehmann and Ban end up with many questions: What is the role of the various neurotransmitters? Does drug response help with the crucial question-is there one schizophrenia, or several, or very many? Can the downside of psychopharmacotherapy, the side effects, teach us anything about schizophrenia? What about alternative therapies; are they adjunctive or symptomspecific or should they be reserved for the nonresponders? Alternatively, can treatment for schizophrenia be conceived of as stage-related, with different stages requiring their own specific therapies? This excellent paper ends with an inquiry into treatments that target intracellular second-messenger systems, the promise of a new era.
What do epidemiologists and pharmacologists have in common? They both use their tools, their very different tools, to get at the mystery of illness causation. Put them together in a room and they would have much to talk about. First, they would talk about what is schizophrenia? Tiring of that, they would go on to what causes schizophrenia, hoping that their different methods, forever being perfected, will eventually generate the answers both groups seek.
